Immunity Pharma
Compounds for Treating Neurodegenerative Diseases
Company Overview
Snapshot
Founded in March 2007, Immunity Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing therapies for neurodegenerative diseases. In September 2020, Immunity Pharma announced promising interim results from its Phase 1/2a study of IPL344 for ALS.
Business overview
Immunity Pharma (IPL) is a Health Tech & Life Sciences company focused on developing therapies for neurodegenerative diseases, with an initial emphasis on Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. The company's core technology involves peptide-based drugs that stimulate therapeutic cell-signaling processes to mitigate disease progression by reducing inflammation and programmed cell death. Immunity Pharma serves the pharmaceutical and healthcare industries by bringing innovative treatments to market.
Strategic signal
In September 2020, Immunity Pharma announced promising interim results from its Phase 1/2a clinical study of IPL344 for ALS. This development is a significant signal for investors, indicating potential clinical validation and progress in addressing a challenging neurodegenerative condition, which could de-risk future development and attract further investment in the biopharmaceutical sector.
Company Intelligence Q&A
- What is Immunity Pharma's primary focus?
- Immunity Pharma primarily focuses on developing therapies for neurodegenerative diseases, with an initial emphasis on Amyotrophic Lateral Sclerosis (ALS).
- What is IPL344?
- IPL344 is Immunity Pharma's lead drug candidate, a peptide-based compound designed to stimulate therapeutic cell-signaling processes to mitigate disease progression in neurodegenerative conditions like ALS.
- What was the key clinical development for IPL344?
- In September 2020, Immunity Pharma announced promising interim results from its Phase 1/2a clinical study of IPL344 in ALS patients.
- From where did IPL344 originate?
- IPL344 originated from the research laboratory of Professor Irun Cohen at the Weizmann Institute of Science in Israel.
- What is the current product stage of Immunity Pharma?
- Immunity Pharma's products, including IPL344, are currently in the Clinical Trial stage.